Alzheimer’s drug offers hope for end to psychosis

by | Feb 19, 2018 | Dementia, News

Pimavanserin targets the THT2A nerve receptor

new drug promises to spare hundreds of thousands of Alzheimer’s sufferers from “terrifying” hallucinations and paranoia, researchers have announced. Scientists have successfully tested the first medicine capable of treating psychosis, which affects around half of patients with the disease, without the devastating side-effects caused by current drugs.

Published in the Lancet Neurology, the trial of pimavanserin offers particular hope to those with advanced psychosis, which doctors often describe as the most distressing symptom of Alzheimer’s. Read the article in the Telegraph